Increased Expression of the p-STAT3/IL-17 Signaling pathway in patients with Dermatomyositis.
暂无分享,去创建一个
Jie Yang | Zili Fu | D. Luo | Yiqun Hao | Luyao Zhou | Kai Wang | W. Jia | Bo Yang | Dong-bin Li | Bo Yang
[1] M. Gatto,et al. Lymphocyte immunophenotyping in inflammatory myositis: a review , 2021, Current opinion in rheumatology.
[2] Guifen Shen,et al. Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy , 2021, International journal of rheumatic diseases.
[3] W. El-Rifai,et al. NF-kB-dependent activation of STAT3 by H. pylori is suppressed by TFF1 , 2021, Cancer Cell International.
[4] A. Ogdie,et al. Persistent premature mortality gap in dermatomyositis and polymyositis: a United Kingdom general population-based cohort study. , 2020, Rheumatology.
[5] M. Khamaisi,et al. Mortality in Patients with Polymyositis and Dermatomyositis in an Israeli Population. , 2020, The Israel Medical Association journal : IMAJ.
[6] Y. Hathout,et al. Serum protein biomarkers for juvenile dermatomyositis: a pilot study , 2020, BMC Rheumatology.
[7] Wei Huang,et al. Targeting STAT3 in Cancer Immunotherapy , 2020, Molecular cancer.
[8] J. Lamb,et al. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018 , 2019, Neuromuscular Disorders.
[9] Kai Zhu,et al. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? , 2019, European journal of medicinal chemistry.
[10] Yuxuan Li,et al. Interleukin-35: A Serological Biomarker for Patients with Polymyositis/Dermatomyositis. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[11] D. Isenberg,et al. Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. , 2019, Rheumatology.
[12] S. Gaffen,et al. The IL-17 Family of Cytokines in Health and Disease. , 2019, Immunity.
[13] Dongping Yuan,et al. Yangyin Qingre Huoxue Method in Traditional Chinese Medicine Ameliorates Atherosclerosis in ApoE−/− Mice Suffering from High-Fat Diet and HSP65 Aggression , 2019, Evidence-based complementary and alternative medicine : eCAM.
[14] A. Mammen,et al. Classification and management of adult inflammatory myopathies , 2018, The Lancet Neurology.
[15] C. Sotiriou,et al. p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial. , 2017, International journal of oncology.
[16] W. Jiang,et al. The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway , 2017, Oncotarget.
[17] Ding Luo,et al. IL-17 Activates the IL-6/STAT3 Signal Pathway in the Proliferation of Hepatitis B Virus-Related Hepatocellular Carcinoma , 2017, Cellular Physiology and Biochemistry.
[18] T. Dai,et al. Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis , 2017, Chinese medical journal.
[19] Y. Parman,et al. Elevated IL-4 and IFN-γ Levels in Muscle Tissue of Patients with Dermatomyositis. , 2017, In vivo.
[20] M. Veldhoen. Interleukin 17 is a chief orchestrator of immunity , 2017, Nature Immunology.
[21] A. Cavani,et al. IL‐17 and IL‐22 in immunity: Driving protection and pathology , 2017, European journal of immunology.
[22] C. Crowson,et al. Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis , 2017, The Journal of Rheumatology.
[23] M. Santis,et al. The Immune Response and the Pathogenesis of Idiopathic Inflammatory Myositis: a Critical Review , 2017, Clinical Reviews in Allergy & Immunology.
[24] Oakley,et al. 213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18–20 September 2015 , 2016, Neuromuscular Disorders.
[25] O. Harismendy,et al. Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance. , 2016, Cell reports.
[26] N. Esa,et al. Allicin Alleviates Dextran Sodium Sulfate- (DSS-) Induced Ulcerative Colitis in BALB/c Mice , 2015, Oxidative medicine and cellular longevity.
[27] I. Lundberg,et al. Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies , 2015, Scandinavian journal of rheumatology.
[28] T. Macdonald,et al. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth , 2014, Oncogene.
[29] F. Iannone,et al. Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies. , 2014, Reumatismo.
[30] Andrew McKenzie,et al. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation , 2014, Science Translational Medicine.
[31] A. Rizzo,et al. Activated IL-22 pathway occurs in the muscle tissues of patients with polymyositis or dermatomyositis and is correlated with disease activity. , 2014, Rheumatology.
[32] H. Yamanaka,et al. IL-6, IL-8, and IL-10 Are Associated with Hyperferritinemia in Rapidly Progressive Interstitial Lung Disease with Polymyositis/Dermatomyositis , 2014, BioMed research international.
[33] Q. Tang,et al. Hmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma , 2013, Mediators of inflammation.
[34] J. Gudjonsson,et al. Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation , 2013, The Journal of Immunology.
[35] V. Poli,et al. IL-6, IL-17 and STAT3: a holy trinity in auto-immunity? , 2012, Frontiers in bioscience.
[36] L. Xia,et al. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis , 2011, Scandinavian journal of rheumatology.
[37] P. Miossec,et al. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. , 2010, Arthritis and rheumatism.
[38] C. Tato,et al. Innate IL-17-producing cells: the sentinels of the immune system , 2010, Nature Reviews Immunology.
[39] B. Feldman,et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies , 2010, Arthritis care & research.
[40] Toshio Hirano,et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. , 2008, Immunity.
[41] M. Febbraio,et al. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. , 2008, Physiological reviews.
[42] Toshio Hirano,et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. , 2007, International immunology.
[43] P. Christadoss,et al. Immunization of mice with T cell-dependent antigens promotes IL-6 and TNF-alpha production in muscle cells. , 2006, Cytokine.
[44] R. D. Hatton,et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.
[45] P. Miossec,et al. Interleukin-17 increases the effects of IL-1β on muscle cells: arguments for the role of T cells in the pathogenesis of myositis , 2003, Journal of Neuroimmunology.
[46] J. Steinke,et al. 2. Cytokines and chemokines. , 2003, The Journal of allergy and clinical immunology.